Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
The Biologics Price Competition and Innovation Act of 2009 (?BPCIA?) has a regulatory and dispute resolution framework
inspired by the framework set forth for small-molecule generics under the Hatch-Waxman Act. While similarities do exist,
fundamental differences between the two regulatory frameworks will mean that the first originator and follow-on biosimilar
manufacturers working their way through the process set forth in the BPCIA will be in uncharted and potentially time-
consuming and costly waters. The proposed talk will review the fundamentals of the BPCIA regulatory framework and the system
of disclosures and counter-disclosures required when an application to manufacturer a biosimilar raises the possibility of a claim
for patent infringement. It will also highlight the areas where experience gained in prior patent litigation involving generics will
likely apply and those areas where that experience may be inapplicable. Specific areas of consideration include patent portfolio
management and protection under the BPCIA?s evolving process, pre-litigation patent information disclosures, oversight and
verification of required disclosures and validation, and the shared and specific patent-related challenges originator and biosimilar
manufacturers will face.
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals